VCELVericel Corporation

$2B

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$19M+12.1% YoY

Gross Profit

$11M59.4% margin

Operating Income

-$4M-22.3% margin

Net Income

-$5M-24.5% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

+5.5%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$6M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$122M

Total Liabilities

$32M

Stockholders' Equity

$91M

Cash & Equivalents

$95M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$19M	$17M	+12.1%
Gross Profit	$11M	$9M	+21.6%
Operating Income	-$4M	-$3M	-68.4%
Net Income	-$5M	-$2M	-94.8%

Revenue Segments

Product

$19M100%

VCEL Q2 2018 Earnings — Vericel Corporation Revenue & Financial Results | Market Cap Arena